Consumer Information for: ANGIOMAX
Consumer Information
Information about the product including what the product is used for, dosage, warnings, proper use and side effects. This summary will not tell you everything about the product. Contact your healthcare professional if you have any questions about the product.
What the medication is used for
Angiomax is an anticoagulant, a medication that prevents blood from clotting. It is used to treat patients with ST-segment elevation myocardial infarction (a type of heart attack) undergoing Percutaneous Coronary Intervention (PCI), (a procedure that unblocks narrowed coronary arteries without having to perform surgery). It is also used to treat patients with moderate- to high-risk acute coronary syndromes (ACS) due to unstable angina or non-ST segment elevation myocardial infarction (a type of heart attack) undergoing PCI, or who will be managed with medicines only, or who will have cardiac (heart) surgery called a Coronary Artery Bypass Graft (CABG) (sometimes referred to as “bypass” surgery). Heparin is also a drug that prevents blood from clotting and is commonly used in patients with cardiovascular disease during PCI or cardiac surgery. Rarely, a patient can develop antibodies to heparin that put them at risk for developing a clot if exposed to heparin. Angiomax is used instead of heparin in these cases when these patients must undergo PCI or cardiac surgery.
What it does
Angiomax is a direct thrombin-inhibitor that prevents blood from clotting during and after PCI or cardiac surgery.
When it should not be used
Angiomax should not be used in patients with:
- A history of any allergic or other severe reaction to Angiomax or any of its components (see ‘What the nonmedicinal ingredients are’ below)
- Uncontrollable active bleeding
- Major blood clotting disorders
- Acute stomach or intestinal ulcer
- Bleeding in the brain
- Severe trauma to the brain or spine
- Inflammation of the heart valves or inner layer of the heart wall caused by bacterial infections
- Severe uncontrolled high blood pressure
- An eye problem called “retinopathy” caused by diabetes or bleeding
- Use of spinal/epidural anaesthesia
What the medicinal ingredient is
Bivalirudin
What the non-medicinal ingredients are
Mannitol, sodium hydroxide, trifluoroacetate
What dosage form it comes in
Angiomax is available as a powder (250 mg) for intravenous (IV) injection after dilution.
Warnings and precautions
Angiomax (bivalirudin) should not be administered into
muscle.
BEFORE you use Angiomax talk to your doctor or pharmacist
if:
- You are at risk of experiencing bleeding
- You are pregnant, planning on becoming pregnant or are breast feeding. Angiomax should not be used during pregnancy, unless clearly necessary. Your doctor will decide whether or not this treatment is appropriate for you.
- You are taking blood thinners or medicines to prevent blood clots (anticoagulants e.g., warfarin, dabigatran, apixaban, rivaroxaban, ASA, clopidogrel, prasugrel, ticagrelor).
The safety and effectiveness of Angiomax in brachytherapy (a
type of radiation therapy) has not been studied. Therefore,
Angiomax is not recommended for use in brachytherapy
procedures.
As with any drug that prevents blood from clotting, bleeding may
occur during or after your PCI or cardiac surgery. You may be at
an increased risk for bleeding if you are elderly, female or are
being given other drugs also known to cause bleeding like heparin
or warfarin. Early signs of bleeding include nose or gum bleeds,
blood in urine or stool, bruising easily and/or the appearance of a
rash of round, red spots under the skin. If you are concerned
about your risk for bleeding or experience any of these symptoms
after your PCI or cardiac surgery, talk to your doctor
immediately.
In patients undergoing cardiac surgery it is often necessary to
receive a blood transfusion. This is true whether the doctor uses
Angiomax or heparin during your medical procedure. In
patients undergoing PCI, the need for transfusions is less
common.
The safety and effectiveness of Angiomax has not been
studied in children.
Interactions with this medication
No formal drug interaction studies have been carried out with
bivalirudin. Use of Angiomax together with heparin, warfarin,
thrombolytics (drugs that break up blood clots) or glycoprotein
IIb/IIIa (GPIIb/IIIa) inhibitors (drugs that prevent platelets from
binding together) is associated with an increased risk of bleeding
events.
Solid particles form when Angiomax is given in the same
intravenous (IV) line as alteplase, amiodarone HCl, amphotericin
B, chlorpromazine HCl, diazepam, prochlorperazine edisylate,
reteplase, streptokinase, and vancomycin HCl. Therefore, they
should not be administered in the same intravenous line with
Angiomax.
Solid particles can form when Angiomax is given in the same
IV line as Dobutamine HCl, Famotidine, Haloperidol lactate,
Labetalol HCl, Lorazepam, and Promethazine HCl. Therefore, the
administration of these medicinal products in the same intravenous
line as Angiomax is not recommended.
Angiomax is administered via an intravenous line from a glass
bottle or polyvinyl chloride bags.
Proper use of this medication
Angiomax is only administered by trained medical
professionals through an intravenous line.
Angiomax will be administered to you after it has been
dissolved in sterile water and diluted to a final concentration of 5
mg/mL.
As with all intravenous (IV) mixtures, Angiomax should be
inspected visually for clarity, solid particles, discolouration and
leakage prior to administration whenever solution and container
permit. Solutions showing haziness, solid particles, discolouration
or leakage should not be used. Discard unused portion.
Usual Dose
The dose of Angiomax you will receive will be based on your weight and will depend on what procedure, PCI or cardiac surgery, you are going to have.
ACS
Angiomax should be given as an IV bolus dose of 0.1 mg/kg
followed by an infusion of 0.25 mg/kg/hr through the angiography
procedure for as long as needed.
If you are going to undergo the PCI procedure, you will receive an
additional IV bolus dose of 0.5 mg/kg at the start of the procedure,
and this will be increased to 1.75 mg/kg/hr for the entire
procedure. After the procedure, your doctor may decide to give
you a reduced infusion dose for as long as needed.
If you are going to undergo off-pump cardiac surgery, you will
receive an additional IV bolus dose of 0.5 mg/kg just before
surgery followed by a 1.75 mg/kg/h dose during the entire
procedure.
If you are going to undergo on-pump cardiac surgery, the initial
infusion will be continued until 1 hour before the procedure at
which point you will be treated with unfractionated heparin.
PCI
Angiomax should be given as an IV bolus dose of 0.75 mg/kg
followed by an infusion of 1.75 mg/kg/hr for the entire procedure.
Your doctor may decide to continue it for 4 hours after your
procedure, and you may be continued on an infusion at a reduced
dose of 0.25 mg/kg/hr for 4-12 hours, as needed. Angiomax is
intended for use with acetylsalicylic acid (ASA) and may be used
with clopidogrel. If you have severe kidney disease, the infusion
dose may have to be reduced to 1.0 mg/kg/hr. If you are on
dialysis, the infusion rate should be reduced to 0.25 mg/kg/hr.
Cardiac Surgery
On-pump Cardiac Surgery: Angiomax should be given as an
IV bolus dose of 1.0 mg/kg followed by an infusion of 2.5
mg/kg/hr. Angiomax infusion may be terminated
approximately 15 minutes prior to the anticipated end of
cardiopulmonary bypass (CPB). If CPB is not terminated within
20 minutes or if you need to go back on bypass, a bivalirudin IV
bolus of 0.5 mg/kg should be administered and a 2.5 mg/kg/hr i.v.
infusion restarted and continued until 15 minutes prior to the
anticipated end of CPB.
Off-pump Cardiac Surgery: Angiomax should be given as an
IV bolus dose of 0.75 mg/kg followed by an infusion of 1.75
mg/kg/hr for the duration of the procedure.
Patients with severe kidney disease have not been studied in
cardiac surgery using Angiomax.
Angiomax can be started 30 minutes after discontinuation of
unfractionated heparin and 8 hours after discontinuation of low
molecular weight heparin.
Angiomax can be used with a glycoprotein IIb/IIIa
(GPIIb/IIIa) inhibitor (drug that prevents platelets from binding
together).
Overdose
Overdosage with single bolus doses of Angiomax up to 7.5 mg/kg may result in increased bleeding or adverse events. If overdose occurs, Angiomax should be discontinued and the patient should be monitored closely for signs of bleeding. Supportive therapy to treat any symptoms should be started as needed. Once the administration of Angiomax has been stopped, there is a gradual reduction in the risk for bleeding as the body breaks down the drug. There is no known antidote to Angiomax. Angiomax is removed from the blood by dialysis.
Side effects and what to do about them
Side effects that have been observed with Angiomax have also
been observed with other drugs that prevent blood clotting such as
heparin. Although the adverse events listed below have been
reported when Angiomax was used, it does not necessarily mean
that Angiomax caused the event. The side effects listed below are
for your information and if you have any concerns or think you
are experiencing an adverse reaction, talk to your doctor or
pharmacist immediately.
Common side effects:
The most common serious side effect of treatment with Angiomax
is major bleeding which could occur anywhere inside the body
[e.g., stomach, digestive system (including vomiting blood or passing blood with the stools), abdomen, lungs, groin, bladder,
heart, eye, ear, nose, or brain). This may rarely result in a stroke or
be fatal. Swelling or pain in the groin or the arm, back pain,
bruising, headache, coughing blood, pink or red urine, sweating,
feeling faint or sick or dizzy due to low blood pressure may be
signs of internal bleeding. Bleeding is more likely to occur when
Angiomax is used in combination with other anticoagulant or
antithrombotic medicines (see INTERACTIONS WITH THIS
MEDICINE).
In clinical studies during and after PCI, common side effects
reported with Angiomax were: angina, collapsed lung, indigestion,
nausea, nervousness, pain at the injection site, trouble sleeping,
haematoma (localized swelling filled with blood) and vomiting.
In clinical studies during and after cardiac surgery, common side
effects with Angiomax were: anxiety, constipation, fluid build-up
in the chest cavity, nausea, and vomiting.
Uncommon side effects:
Thrombosis (blood clot) which may result in serious or fatal
complications such as heart attack.
Rare side effects:
Other side effects that occurred rarely with Angiomax included:
decreased platelet count, hives, rash, and coronary artery
thrombosis (blood clot in the heart arteries or within a stent being
felt as a heart attack) which can also be fatal and/or thrombosis in
the catheter.
During routine medical use with Angiomax, the following side
effects have been reported: clot formation during PCI, and fatal
bleeding.
Symptom / effect | Talk with your doctor, nurse, or pharmacist only if severe | Talk with your doctor, nurse, or pharmacist in all cases | Stop taking drug and call your doctor or pharmacist |
---|---|---|---|
Common | |||
Anaemia | ✔ | ||
Decreased blood pressure | ✔ | ||
Difficulty urinating or decreased urine volume | ✔ | ||
Fever (with or without cough and/or difficulty breathing) | ✔ | ||
Headache | ✔ | ||
Heart attack | ✔ | ||
Heart rate changes (decreased, increased or irregular) which can be lifethreatening when not treated | ✔ | ||
Increased blood pressure | ✔ | ||
Pain (including back, pelvic/ abdominal, or chest pain) | ✔ | ||
Swelling of the hands and/or feet | ✔ | ||
Uncontrolled bleeding | ✔ | ||
Wound secretion | ✔ | ||
Uncommon | |||
Allergic or hypersensitivity reactions | ✔ | ||
Stroke | ✔ |
How to store
As Angiomax is a hospital product only, storage of Angiomax is the responsibility of healthcare professionals.
Store at controlled room temperature (15 – 25°C). Do not freeze. Discard any unused portion of the reconstituted solution remaining in the vial.
Reporting side effects
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:
- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
- Fax toll-free to 1-866-678-6789, or
- Mail to: Canada Vigilance Program
Health Canada
Postal Locator 0701E
Ottawa, Ontario
K1A 0K9
Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.
NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.
More information
This document plus the full product monograph, prepared for
health professionals can be found by contacting the sponsor,
Sandoz Canada Inc., at:
1-800-361-3062
or by written request at:
145 Jules-Léger
Boucherville, Québec, Canada
J4B 7K8
Or by e-mail at :
medinfo@sandoz.com
This leaflet was prepared by Sandoz Canada Inc.
Last revised: September 28, 2016
Related Drug Products
Product name | DIN | Company name | Active ingredient(s) & strength |
---|---|---|---|
THYMOGLOBULIN | 02246805 | SANOFI-AVENTIS CANADA INC | ANTI-THYMOCYTE GLOBULIN (RABBIT) 25 MG / VIAL |